Novo Nordisk announced the latest research results of oral semaglutide: average weight loss of 16.6%

On September 23, reporters learned from Novo Nordisk that recently, the New England Journal of Medicine published results from the Phase 3 trial OASIS 4. This trial evaluated the efficacy and safety of the investigational once-daily oral semaglutide tablet at 25 mg. The results showed that at 64 weeks, among all patients adhering to treatment, those in the oral semaglutide tablet 25 mg group achieved an average weight reduction of 16.6%, while the placebo group had a reduction of 2.7%; more than one-third of patients in the oral semaglutide tablet 25 mg group achieved a weight reduction of 20% or more, compared to 2.9% in the placebo group. These figures are comparable to the results of previous trials conducted with Wegovy injections. In February of this year, Novo Nordisk submitted a new drug application for the once-daily Wegovy oral tablet to the U.S. FDA, with approval expected by the end of this year. Currently, no GLP-1 oral tablets for weight loss have been approved. Novo Nordisk has significantly expanded its production facilities and has begun manufacturing this product